NCT00453986 - Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old Adults | Biotech Hunter

Enrollment

1,352

Participants

Timeline

Start Date

April 9, 2007

Primary Completion Date

November 30, 2007

Study Completion Date

May 21, 2008

Conditions

Infections, Meningococcal

Interventions

BIOLOGICAL

Meningococcal vaccine GSK134612

One intramuscular dose

BIOLOGICAL

Mencevax™ACWY

One subcutaneous dose

BIOLOGICAL

Fluarix™

One intramuscular dose

Trial Locations (4)

GSK Investigational Site, Cavite

GSK Investigational Site, Beirut

GSK Investigational Site, City of Muntinlupa

GSK Investigational Site, Manila